ALZN ALZAMEND NEURO INC revenue, earnings and financials
For the quarter ended July 31, 2026, ALZAMEND NEURO INC reported revenue of n/a, net income of −$3.03M and diluted EPS of −$0.68; for the fiscal year ended April 2026 revenue was n/a.
ALZN annual revenue and earnings
- Fiscal year ended Apr 2026: revenue n/a, gross profit n/a, operating income −$8.77M, net income −$8.77M (margin n/a), EPS −$2.63
- Fiscal year ended Apr 2025: revenue n/a, gross profit n/a, operating income −$4.50M, net income −$4.51M (margin n/a), EPS −$11.32
- Fiscal year ended Apr 2024: revenue n/a, gross profit n/a, operating income −$9.94M, net income −$9.95M (margin n/a), EPS −$132.33
- Fiscal year ended Apr 2023: revenue n/a, gross profit n/a, operating income −$14.9M, net income −$14.9M (margin n/a), EPS −$22.89
- Fiscal year ended Apr 2022: revenue n/a, gross profit n/a, operating income −$12.3M, net income −$12.4M (margin n/a), EPS −$0.14
ALZN quarterly revenue and earnings
- Quarter ended Jul 31, 2026: revenue n/a, net income −$3.03M, EPS −$0.68
- Quarter ended Apr 30, 2026 (from the annual report): revenue n/a, net income −$2.87M, EPS −$0.47
- Quarter ended Jan 31, 2026: revenue n/a, net income −$2.20M, EPS −$0.58
- Quarter ended Oct 31, 2025: revenue n/a, net income −$1.00M, EPS −$0.30
- Quarter ended Jul 31, 2025: revenue n/a, net income −$2.70M, EPS −$1.28
- Quarter ended Apr 30, 2025 (from the annual report): revenue n/a, net income −$1.14M, EPS $5.46
- Quarter ended Jan 31, 2025: revenue n/a, net income −$1.04M, EPS −$1.75
- Quarter ended Oct 31, 2024: revenue n/a, net income −$1.36M, EPS −$3.61
- Quarter ended Jul 31, 2024: revenue n/a, net income −$974K, EPS −$11.42
- Quarter ended Apr 30, 2024 (from the annual report): revenue n/a, net income −$852K, EPS −$118.75
- Quarter ended Jan 31, 2024: revenue n/a, net income −$2.66M, EPS −$3.77
- Quarter ended Oct 31, 2023: revenue n/a, net income −$2.91M, EPS −$4.43
- Quarter ended Jul 31, 2023: revenue n/a, net income −$3.53M, EPS −$5.38
- Quarter ended Apr 30, 2023 (from the annual report): revenue n/a, net income −$3.31M, EPS −$21.55
- Quarter ended Jan 31, 2023: revenue n/a, net income −$5.43M, EPS −$0.83
- Quarter ended Oct 31, 2022: revenue n/a, net income −$3.11M, EPS −$0.48
- Quarter ended Jul 31, 2022: revenue n/a, net income −$3.04M, EPS −$0.03
- Quarter ended Apr 30, 2022 (from the annual report): revenue n/a, net income −$3.87M, EPS −$0.04
- Quarter ended Jan 31, 2022: revenue n/a, net income −$2.57M, EPS −$0.03
- Quarter ended Oct 31, 2021: revenue n/a, net income −$3.60M, EPS −$0.04
ALZN cash flow, buybacks and dividends
- Fiscal year ended Apr 2026: operating cash flow −$8.07M, share buybacks n/a
- Fiscal year ended Apr 2025: operating cash flow −$6.57M, share buybacks n/a
- Fiscal year ended Apr 2024: operating cash flow −$8.27M, share buybacks n/a
- Fiscal year ended Apr 2023: operating cash flow −$8.92M, share buybacks n/a
- Fiscal year ended Apr 2022: operating cash flow −$6.61M, share buybacks n/a
ALZN balance sheet
- Jul 31, 2026: cash $7.59M, total assets $8.54M, total liabilities $2.74M, shareholders' equity $5.80M
- Apr 30, 2026: cash $711K, total assets $2.08M, total liabilities $1.35M, shareholders' equity $733K
- Jan 31, 2026: cash $2.71M, total assets $4.04M, total liabilities $1.86M, shareholders' equity $2.20M
- Oct 31, 2025: cash $4.45M, total assets $5.09M, total liabilities $717K, shareholders' equity $4.37M
- Jul 31, 2025: cash $5.62M, total assets $6.33M, total liabilities $983K, shareholders' equity $5.34M
- Apr 30, 2025: cash $3.95M, total assets $4.60M, total liabilities $635K, shareholders' equity $3.97M
- Jan 31, 2025: cash $3.36M, total assets $4.18M, total liabilities $726K, shareholders' equity $3.45M
- Oct 31, 2024: cash $4.09M, total assets $5.01M, total liabilities $1.25M, shareholders' equity $3.75M
Is ALZN profitable?
No. ALZAMEND NEURO INC lost $9.10M over the last four quarters.
What is ALZN's EPS?
Diluted earnings per share over the last four quarters were −$2.03; −$0.68 in the latest quarter.